Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2016 08:00 ET | Source: Chiasma, Inc.

Chiasma to Participate in AACE and ECE 2016 Conferences

Publishes New Data Regarding Time-Weighted Average Response Rate from Initial Phase 3 Trial Presents New Injectable Somatostatin Analog Patient Reported Outcome Data Highlights Recently...
May 11, 2016 16:01 ET | Source: Chiasma, Inc.

Chiasma Reports First Quarter 2016 Results

WALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company developing an investigational new drug, Mycapssa™ (octreotide) capsules, for the potential...
May 03, 2016 08:00 ET | Source: Chiasma, Inc.

Chiasma to Report First Quarter 2016 Financial Results on May 11, 2016

WALTHAM, Mass., May 03, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company developing an investigational new drug, octreotide capsules, for the maintenance treatment...
April 29, 2016 08:00 ET | Source: Chiasma, Inc.

Chiasma to Participate in Acromegaly Community Conference

WALTHAM, Mass., April 29, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company developing an investigational new drug, octreotide capsules, for the maintenance...
April 18, 2016 06:00 ET | Source: Chiasma, Inc.

Chiasma Provides Update Regarding FDA’s Complete Response Letter for Mycapssa™ New Drug Application

WALTHAM, Mass., April 18, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today...
April 15, 2016 18:26 ET | Source: Chiasma, Inc.

FDA Issues Complete Response Letter for Mycapssa™ New Drug Application

WALTHAM, Mass., April 15, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
March 31, 2016 08:00 ET | Source: Chiasma, Inc.

Chiasma Announces Upcoming Events at ENDO 2016

WALTHAM, Mass., April 14, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, an investigational new oral drug...
March 14, 2016 16:01 ET | Source: Chiasma, Inc.

Chiasma Reports Fourth Quarter and Year End 2015 Results

Initiates Pivotal EU Phase 3 Trial Expands Organization in Advance of PDUFA Date Provides Operating Expense Guidance for 2016 NEWTON, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc....
March 14, 2016 08:00 ET | Source: Chiasma, Inc.

Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly

Seeks to Demonstrate Non-Inferiority of Mycapssa™ to Monthly Injections Approximately 150 Patients Targeted for Enrollment NEWTON, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc.,...
February 29, 2016 08:00 ET | Source: Chiasma, Inc.

Chiasma Joins Patient Organizations Worldwide in Support of Rare Disease Day

NEWTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company, today announced its support for Rare Disease Day 2016. In honor of Rare...